- Before
- Builds the impact assessment by hand for every new CCDS, and learns a market is late when it has already missed its date.
- Now
- Starts from a redline, an impact matrix and 16 open country tasks; decides only the deviations and diverging edits that need her.
One safety-critical CCDS change, from committee approval to every market
Veltrimab CCDS 15.0 adds a warning for drug-induced liver injury after signal SIG-2026-031. It has to reach 16 markets by Nov 1. Here is day 5 of its clock, screen by screen, in the working solution.
- 01Morning
Every market, on one map
Dr. Maya Chen · Global labeling leadMaya opens the cascade map: Veltrimab 15.0, safety-critical, day 5 of 30 to submit in 16 markets. 15 of 16 markets are on track, the deadline is 25 days away, and five things wait for her — a deviation to decide in Brazil, a diverging edit in Mexico, Talmirex CCDS 23.0 approved this morning, and Turkey and South Africa late on Corventa 9.0.
“Meaning Checker · Re-checked 9 affiliate edits since yesterday — 8 keep the CCDS meaning, 1 does not (Mexico).”
- 02Oct 2 · 16:07
Five changes, in redline, each with its class
CCDS Comparer · Safety Change ClassifierThe comparer aligned 14.2 and 15.0 section by section and found five changes, layout edits ignored. §4.4 gets a new warning for drug-induced liver injury, with liver enzymes and bilirubin measured before treatment and periodically thereafter — safety-critical. §4.8 adds liver injury as uncommon and moves urticaria to common; §4.6 adds pregnancy registry data; §4.2 and §5.2 are editorial. Omar Haddad, the safety physician, confirmed the safety-critical class.
Why it changed: 27 cases of drug-induced liver injury, 3 with acute liver failure; PRAC asked for §4.4 and §4.8 to change within 60 days.
- 03Oct 2 · 16:11
Every market and section the change lands in
Label Impact MapperThe impact matrix shows each change against each market: Update where the text must change, Aligned where the local label already says it, Deviation where a registered local wording covers the passage, Diverging where an edit changes the meaning. Across 16 markets and 26 local labels: 68 sections to update, 5 already aligned, 5 deviations or edits to check.
The mapper never marks a passage aligned without a cited local sentence, and registered deviations always go to a person.
- 04Oct 2 · 16:21
A country task for every market, with its procedure
Deadline PlannerSixteen country tasks open with the procedure from the registration data and an owner in each market: a CBE-0 supplement for the US, already submitted on Oct 6; an SNDS-C for Canada; a Type II variation for the EU, due Nov 25; a notificação de alteração de texto de bula for Brazil. Turkish, Japanese, Chinese and Korean are with the translation vendor, back Oct 9 to 14.
- 05Your decision
The bula drafted — and the ANVISA wording kept
Local Text DrafterThe Brazil draft of the bula profissional, section 5 Advertências e precauções, is built sentence by sentence: approved translations used as they are, a 94 % close match adjusted, and the patient wording for the bula paciente. Brazil has a registered deviation, DEV-BR-004: ANVISA asked in 2024 for liver tests before treatment and every 3 months. The drafter kept that sentence and asks Maya.
“Keep the ANVISA wording — liver tests before treatment and every 3 months — stricter than the CCDS, so the core safety information is still met.”
- 06Signed
Approved, e-signed, sent to the affiliate
Dr. Maya Chen · Global labeling leadMaya keeps the deviation, and the register re-confirms it. She approves the Brazil draft — bula profissional and bula paciente — with her password; the signature, its meaning (“Approved by the global labeling lead”) and the time are stored with the record. Rafael Souza, the affiliate regulatory manager in Brazil, has it for affiliate review.
- 07Oct 6 · 17:43
An affiliate edit that drops a safety instruction
Meaning CheckerIn Mexico, Ana Torres shortened the IPP draft “for space in the IPP reducida” and removed “y periódicamente después”. The Meaning Checker back-translated the edit and flagged it: patients would be tested only once before treatment — weaker than CCDS 15.0 — and no registered deviation covers it.
Three choices: send back with the CCDS sentence, escalate to the Americas head, or accept with a justification and Safety sign-off.
- 08One click
Sent back, with the sentence restored
Dr. Maya Chen · Global labeling leadMaya sends the edit back to Ana Torres. The CCDS sentence is restored in the draft, the Meaning Checker re-checks the next edit, and the decision is on the activity record of the change.
- 0908:10 · arrived today
The next CCDS, analysed the day it is approved
The agentsTalmirex CCDS 23.0 was approved by the labeling committee this morning after signal SIG-2026-038: a new warning for Stevens-Johnson syndrome and toxic epidermal necrolysis. Maya uploads it and the six agents run: 3 changes, 26 local labels, 44 sections to update, 1 already aligned and 2 deviations to check — Brazil’s ANVISA patient-alert sentence among them. 16 country tasks open, submit by Nov 6.
- 10Every month
How fast changes reach every label
Dr. Maya Chen · Global labeling leadOver 12 months: 1,184 local label revisions across 30 products and 16 markets, a median of 31 days from CCDS approval to local submission against a 30-day target, and 89 % submitted on time. Where the days go now: impact assessment 2.6 days, translation 9.4, health-authority review 21.
“Impact assessment and drafting take hours, not weeks, once the agents do them; translation and health-authority review remain the long steps.”